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Critical neutralizing fragment of Zika virus
EDIII elicits cross-neutralization and
protection against divergent Zika viruses
Wanbo Tai1,2, Lei He3, Yufei Wang1, Shihun Sun2, Guangyu Zhao2, Chuming Luo4, Pei Li2, Haiyan Zhao5,
Daved H. Fremont5, Fang Li4, Shibo Jiang1,6, Yusen Zhou2,3 and Lanying Du1
Abstract
Zika virus (ZIKV) infection remains a serious health threat due to its close association with congenital Zika syndrome
(CZS), which includes microcephaly and other severe birth defects. As no vaccines are available for human use,
continuous effort is needed to develop effective and safe vaccines to prevent ZIKV infection. In this study, we
constructed three recombinant proteins comprising, respectively, residues 296–406 (E296-406), 298–409 (E298-409),
and 301–404 (E301-404) of ZIKV envelope (E) protein domain III (EDIII) fused with a C-terminal Fc of human IgG. Our
results demonstrated that E298-409 induced the highest titer of neutralizing antibodies against infection with nine
ZIKV strains isolated from different hosts, countries, and time periods, and it maintained long-term anti-ZIKV
immunogenicity to induce neutralizing antibodies. Pups born to mice immunized with E298-409 were fully protected
against lethal challenge with two epidemic human ZIKV strains, 2015/Honduras (R103451) and 2015/Colombia (FLR).
Passive transfer of anti-E298-409 mouse sera protected pups born to naive mice, as well as type I interferon receptor-
deﬁcient adult A129 mice, from lethal challenge with human ZIKV strains R103451 and FLR, and this protection was
positively correlated with neutralizing antibodies. These data suggest that the critical neutralizing fragment (i.e., a
fragment that can induce highly potent neutralizing antibodies against divergent ZIKV strains) of ZIKV EDIII is a good
candidate for development as an effective and safe ZIKV subunit vaccine to protect pregnant mothers and their
fetuses against ZIKV infection. The E298-409-speciﬁc antibodies can be used for passive immunization to prevent ZIKV
infection in newborns or immunocompromised adults.
Introduction
Zika virus (ZIKV) is an emerging viral pathogen asso-
ciated with severe neurological diseases, including
Guillain–Barre Syndrome (GBS)1,2 and congenital Zika
syndrome (CZS), which includes microcephaly, brain
abnormalities, and other severe birth defects3–7. Increasing
numbers of women have been infected with ZIKV during
pregnancy and have given birth to newborns with con-
genital defects7–10, leading to serious consequences. A
variety of ZIKV vaccines, such as those based on inacti-
vated or live-attenuated viruses, viral vectors, DNA, RNA,
and viral proteins11–17, have been developed against ZIKV
infection in experimental animal models, and several have
progressed to clinical trials18–20. To date, however, no
vaccines are available for human use, a situation calling for
a continuous effort to develop effective and safe vaccines
against ZIKV infection.
ZIKV belongs to the same Flaviviridae family as dengue
virus (DENV), West Nile virus (WNV), Japanese ence-
phalitis virus (JEV), yellow fever virus (YFV), and tick-
borne encephalitic virus (TBEV)21,22. The full-length
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genome of ZIKV encodes structural proteins, such as
capsid (C), membrane (M) or precursor membrane (prM),
and envelope (E), in addition to non-structural proteins
(NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5)21,22,
among which E protein is the major protein for inducing
neutralizing antibodies against ZIKV infection23,24 and,
thus, a main target for developing ZIKV vaccines. ZIKV E
protein consists of domain I (DI), domain II (DII), domain
III (DIII), a stalk region, and a transmembrane domain
(Supplementary Figure S1A)25. A number of ZIKV E-
based vaccines were developed targeting prM-E or full-
length E11,14,16,26, whereas a few have attempted to target
fragments of ZIKV E protein domains, particularly EDIII,
to identify important regions in the E protein for devel-
oping more effective and safer ZIKV vaccines27.
Although ZIKV E protein is a key target for developing
ZIKV vaccines, studies have found that antibodies tar-
geting ZIKV EDI/II are generally cross-reactive and
poorly neutralizing, potently enhancing ZIKV and DENV
infection, whereas those targeting ZIKV EDIII have the
most potent neutralizing activity against ZIKV infection28.
In addition, antibodies targeting DENV and/or WNV E
proteins, including the fusion loop region, may bind and
cross-react with ZIKV EDI/II region, but they do not
neutralize ZIKV infectivity, thus promoting antibody-
dependent enhancement (ADE)29–31.
In this study, we constructed three recombinant proteins
comprising ZIKV EDIII fragments of different lengths and
found that one of the ZIKV EDIII fragments, E298-409,
could induce potent neutralizing antibodies, which pro-
tected newborn mice and type I interferon receptor-
deﬁcient adult A129 mice from lethal challenge with
divergent ZIKV strains. The present study demonstrates
that the identiﬁed EDIII fragment can be further devel-
oped as an effective and safe vaccine for prevention of
ZIKV infection and that the anti-E298-409 antibodies can
be used for pre-exposure prophylaxis of ZIKV infection.
Materials and methods
Ethics statement
Seven-day-old male and female BALB/c pups, 6- to 8-
week-old female BALB/c mice, and 5-week-old male and
female A129 mice were used in the study. The animal
studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The protocols were approved by the Committee on the
Ethics of Animal Experiments of the New York Blood
Center (Permit Numbers: 344.00 and 345.00).
Construction, expression, and puriﬁcation of recombinant
proteins
Recombinant ZIKV EDIII fragments were prepared as
previously described with some modiﬁcations32,33. Brieﬂy,
the genes encoding the respective ZIKV EDIII fragments
were ampliﬁed by PCR using a codon-optimized ZIKV E
(ZikaSPH2015 strain, GenBank accession no.
KU321639.1) plasmid as the template, followed by fusion
with a C-terminal Fc of human IgG (hereinafter E296-406,
E298-409, or E301-404). Recombinant ZIKV E (residues
1–454) fused with a C-terminal Fc (E1-454) was con-
structed as described above. Recombinant ZIKV EDIII
(residues 298–409) containing a C-terminal foldon
sequence and a His6 tag (EDIII-His) was constructed
using the pJW4303 expression vector34. The aforemen-
tioned plasmids were transfected into 293T cells, and the
respective proteins were harvested from the cell culture
supernatants and puriﬁed by Protein A afﬁnity chroma-
tography (for the Fc-tagged proteins) (GE Healthcare,
Port Washington, NY, USA) or Ni-NTA Superﬂow
(for the His-tagged protein) (Qiagen, Germantown,
MD, USA).
SDS-PAGE and western blot
The puriﬁed EDIII fragments were analyzed by SDS-
PAGE and Western blot as previously described32,35.
Brieﬂy, the proteins (boiled or non-boiled) were separated
by 10% Tris-Glycine SDS-PAGE gels and stained by
Coomassie Brilliant Blue or transferred to nitrocellulose
membranes for Western blot analysis. The blots were
blocked with 5% fat-free milk in PBST overnight at 4 °C
and incubated for 1 h at room temperature with a ZIKV
EDIII-speciﬁc mouse monoclonal antibody (mAb), ZV-54
(0.4 μg/ml)36. After three washes, the blots were incubated
with horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG (1:5000, Invitrogen, Waltham, MA, USA) for
1 h at room temperature. The signals were detected with
ECL Western blot substrate buffer and Amersham
Hyperﬁlm (GE Healthcare).
Animal immunization
This procedure was carried out as previously descri-
bed32,35. Brieﬂy, female BALB/c mice were intramuscularly
(i.m.) immunized with EDIII protein fragments (10 μg per
mouse) or PBS control, in the presence of aluminum
(Alum, 500 μg per mouse) and monophosphoryl lipid A
(MPLA, 100 μg per mouse) adjuvants (InvivoGen, San
Diego, CA, USA), and boosted with the same immunogens
at day 21, day 42, month 7, and month 10, respectively.
Sera were collected at months 0, 2, 7, and 10 post immu-
nization to test antibodies and neutralizing antibodies.
ELISA
Mouse sera were analyzed for ZIKV EDIII-speciﬁc anti-
body responses by ELISA as previously described32,35.
Brieﬂy, ELISA plates were coated with ZIKV EDIII-His or
E1-454 protein overnight at 4 °C and blocked with 2% fat-
free milk for 2 h at 37 °C. Serially diluted mouse sera were
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added to the plates and then incubated for 1 h at 37 °C.
After washing, the plates were incubated with HRP-
conjugated anti-mouse IgG (1:5000), anti-mouse IgG1
(1:2000, Bethyl Laboratories, Montgomery, TX, USA), or
anti-mouse IgG2a (1:2000, Invitrogen) for 1 h at 37 °C. The
reaction was detected by 3,3′,5,5′-tetramethylbenzidine
(TMB) substrate (Invitrogen) and stopped by 1 N H2SO4.
The absorbance at 450 nm was measured using an ELISA
plate reader (Tecan, Morrisville, NC, USA), and the
respective antibody titers were calculated.
ZIKV preparation and plaque reduction neutralization test
(PRNT)
ZIKV (human strains, including FLR (2015/Colombia),
R103451 (2015/Honduras), PAN2015 (2015/Panama),
PAN2016 (2016/Panama), PRVABC59 (2015/Puerto
Rico), PLCal_ZV (2013/Thailand), IbH 30656 (1968/
Nigeria), mosquito strain MEX 2-81 (2016/Mexico), and
rhesus strain MR 766 (1947/Uganda)) was ampliﬁed in
Vero E6 cells, and the related viral titers were determined
by a standard plaque-forming assay. A PRNT was then
carried out to measure the titers of neutralizing antibodies
in the collected mouse sera. Brieﬂy, viral solutions of each
ZIKV at ~100 plaque-forming units (PFU) were incubated
with serially diluted sera (e.g., polyclonal antibody, pAb)
or ZV-54 neutralizing mAb control36 for 1.5 h at 37 °C.
The antibody-virus mixtures were transferred onto Vero
E6 cells and incubated for 1 h at 37 °C. The cells were then
overlaid with medium (1% carboxymethyl cellulose in
DMEM containing 2% FBS), cultured at 37 °C for
4–5 days, and further stained with 0.5% crystal violet. The
titers of neutralizing antibodies in mouse sera are pre-
sented as the highest dilution of sera resulting in a com-
plete inhibition of virus infectivity in at least 50% of the
wells (PRNT50). Each serum was tested in duplicate wells
in fourfold serial dilutions from 1:10 to 1:2,560. The
neutralizing activity of mAb was calculated in duplicate
wells at 5-fold serial dilutions from 50 μg/ml and is
expressed as 50% neutralization dose (ND50).
ZIKV challenge in pups born to vaccinated female BALB/c
mice
Seven-day-old pups born to female BALB/c mice vac-
cinated with ZIKV E296-406, E298-409, E301-404, and
PBS, respectively, were challenged intraperitoneally (i.p.)
with 5× 104 PFU of ZIKV R103451 or FLR strains in 50 μl
solution. Mouse survival and weight were observed for
14 days post-viral infection (p.i.).
Passive protection against ZIKV challenge in pups born to
naive female BALB/c mice
Mouse sera immunized with the aforementioned ZIKV
fragments were i.p. injected into 7-day-old naïve BALB/c
pups (100 μl per pup). The sera were diluted in PBS to
produce the same log ELISA titer of 4.00 (104) after
detection of the IgG titers using ZIKV EDIII-His protein.
Six hours later, pups were i.p. challenged with 5× 104
PFU of ZIKV R103451 or the FLR strain as described
above. Pups injected with ZIKV only were included as
sham controls. Some pups also received another dose of
sera 12 h post-challenge with virus. Mouse survival and
weight were recorded for 14 days p.i.
Passive protection against ZIKV challenge in lethal A129 mice
Five-week-old A129 mice were i.p. injected with sera
(200 μl per mouse) (with a ZIKV EDIII-speciﬁc IgG titer
of 105 as described above) from E298-409-immunized
mice. Six hours later, mice were i.p. challenged with 102 or
103 PFU of ZIKV R103451 or FLR strain. Mice challenged
with 103 PFU of ZIKV were further injected with the
above sera (200 μl per mouse) at 12 h, or 12, 24, and 48 h
p.i., respectively. Mice injected with ZIKV only were
included as sham controls. Mouse survival and weight
were evaluated for 14 days p.i. ZIKV RNA titers were
detected from sera and tissues collected at 3 days p.i. as
described below, and pathological changes were detected
from tissues collected at 5 days p.i. by H&E staining as
previously described35,37.
Quantitative reverse transcriptase PCR (qRT-PCR)
ZIKV RNA copies in the sera and tissues of challenged
mice were detected by qRT-PCR as previously descri-
bed38. Brieﬂy, ZIKV RNA was extracted using the
QIAamp MinElute Virus Spin Kit (for sera) (Qiagen) and
the RNeasy Mini Kit (for tissues) (Qiagen). The extracted
ZIKV RNA was quantiﬁed using one-step qRT-PCR with
Power SYBR Green PCR Master Mix, MultiScribe Reverse
Transcriptase, and Ambion RNase Inhibitor (Thermo
Fisher Scientiﬁc, Waltham, MA, USA) in the ViiA 7
Master Cycler PCR System (Thermo Fisher Scientiﬁc)
according to the manufacturers’ instructions. The forward
and reverse primers used for the ampliﬁcation were
5′-TTGGTCATGATACTGCTGATTGC-3′ and 5′-CCTT
CCACAAAGTCCCTATTGC-3′, respectively.
Statistical analysis
The values are presented as the means with standard
error (SE). Statistical signiﬁcance among the different
groups was calculated by Student’s two-tailed t-test using
GraphPad Prism Statistical Software. *, **, and *** indicate
P< 0.05, P< 0.01, and P< 0.001, respectively.
Results
ZIKV EDIII fragments, especially E298-409, induced broad-
spectrum neutralizing antibodies and maintained long-
term immunogenicity
Three ZIKV EDIII fragments comprising residues
296–406, 298–409, and 301–404, respectively, were
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constructed, and each of them was fused with a C-
terminal Fc (Supplementary Figure S1B). Except for E301-
404, which covers the entire sequence of EDIII (residues
301–404), both E296-406 and E298-409 have a few resi-
dues from the EDI and stalk regions (Supplementary
Figure S1C). The recombinant proteins were expressed in
293T cell culture supernatants and puriﬁed with high
purity. They formed dimeric structures and maintained
good conformation (Supplementary Figure S2A). Parti-
cularly, these EDIII fragments were recognized by a mAb
(ZV-54) speciﬁc to ZIKV EDIII protein (Supplementary
Figure S2B)36, demonstrating their strong speciﬁcity to
ZIKV.
To evaluate the immunogenicity of the three EDIII
fragments, we used puriﬁed proteins to immunize female
BALB/c mice following the immunization schedule
described in Supplementary Figure S3A. Sera collected at
2 months after immunization were tested for cross-
neutralization against nine ZIKV strains isolated from
different hosts (human, mosquito, and rhesus), various
countries and regions (Colombia, Honduras, Panama,
Puerto Rico, Thailand, Nigeria, Mexico, and Uganda), and
different periods of time (1947, 1968, 2013, 2015, and
2016) (Supplementary Figure S4A). These ZIKV strains
belong to diverse phylogenetic groups (Supplementary
Figure S4B) and have a number of amino acid variations
among their E proteins (Supplementary Figure S4C).
Compared with the E296-406 and E301-404 fragments,
the E298-409 fragment induced higher titers of neu-
tralizing antibodies able to cross-neutralize all ZIKV
strains tested (Fig. 1), including those with different EDIII
sequences, e.g., PRVABC59 (isolated from a patient in an
American country), IbH 30656 (isolated from a patient in
an African country), and MR 766 (isolated from a rhesus
macaque in an African country), and those with the same
EDIII sequences, e.g., FLR, R103451, PAN2015, PAN2016,
MEX 2-81 (isolated from patients or mosquitoes in
American countries), and PLCal_ZV (isolated from a
patient in an Asian country) (Supplementary Figure S4).
Speciﬁcally, the level of E298-409-elicited neutralizing
antibodies was signiﬁcantly higher than that induced by
either E296-406 or E301-404 against epidemic human
2015 strains FLR (Fig. 1a) and PAN2015 (Fig. 1c),
2013 strain PLCal_ZV (Fig. 1f), and 1968 strain IbH 30656
(Fig. 1g). By comparison, no ZIKV-speciﬁc neutralizing
antibody was detected in the control mice injected with
PBS (Fig. 1). The above results demonstrated that ZIKV
EDIII fragments, particularly E298-409, were capable of
eliciting highly potent neutralizing antibodies against
divergent human, mosquito, and rhesus ZIKV strains
from different countries and years.
To investigate the long-term immunogenicity and
neutralizing activity of the ZIKV EDIII fragments, the
immunized mice were observed for up to 10 months, and
sera were collected at 0, 2, 7, and 10 months post
immunization to test ZIKV EDIII and E-speciﬁc antibody
responses and neutralizing antibodies against two selected
epidemic human strains, R103451 and FLR. The data
from the antibody test revealed that although all three
EDIII fragments were able to elicit long-term EDIII-spe-
ciﬁc IgG antibodies, those induced by the E298-409 and
E301-404 fragments showed signiﬁcantly higher titers
than that induced by the E296-406 fragment (Fig. 2Aa).
These IgG antibodies were further tested using a ZIKV E
protein containing residues 1–454, and the results showed
that the E-speciﬁc IgG antibodies corresponded to the
respective EDIII-speciﬁc IgG antibodies induced by the
three EDIII fragments (Fig. 2Ab). Compared to E301-404,
E298-409 elicited a relatively higher titer of EDIII-speciﬁc
IgG1 (Th2-associated) antibodies (Fig. 2Ac) but a similar
level of IgG2a (Th1-associated) antibodies (Fig. 2Ad).
E296-406 induced the lowest titers of IgG1 and IgG2a
antibodies among the three fragments in the test months
(Fig. 2Ac, d). E298-409 elicited more potent long-term
neutralizing antibody responses than E296-406 and E301-
404 against ZIKV R103451 (Fig. 2Ba) and FLR (Fig. 2Bb)
strains for at least 10 months (Fig. 2B). In contrast, con-
trol PBS induced only background levels of IgG, IgG1, and
IgG2a antibody responses and neutralizing antibodies
against the two tested ZIKV strains (Fig. 2). The above
data indicate that ZIKV EDIII fragments, especially E298-
409, maintained the immunogenicity required to elicit
long-term EDIII and E-speciﬁc antibody responses, par-
ticularly neutralizing antibody responses against infection
with variant epidemic human ZIKV strains.
ZIKV EDIII fragments protected pups born to immunized
BALB/c mice against challenge with divergent epidemic
human ZIKV strains
Having conﬁrmed the immunogenicity of ZIKV EDIII
fragments, we next wanted to know whether the anti-
bodies induced by these proteins could protect against
ZIKV infection in animal models in vivo. Seven-day-old
newborn mice (pups) are a convenient and effective
means for evaluating the protective efﬁcacy of ZIKV
vaccines, as they are highly susceptible to ZIKV infec-
tion17. Therefore, we initially used pups born to immu-
nized female BALB/c mice at 7 months post
immunization for ZIKV challenge (Supplementary Fig-
ure S3B). Theoretically, if pups receive anti-ZIKV neu-
tralizing antibodies from their mothers during pregnancy,
they are expected to be protected against ZIKV infection.
To test the protective efﬁcacy of ZIKV EDIII fragments,
pups were challenged with 5× 104 PFU of the afore-
mentioned two epidemic human ZIKV strains, R103451
and FLR, and the resulting survival and weight, as well as
the neutralizing antibodies from mothers and pups, were
evaluated.
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Except for the pups from mice immunized with E301-
404, which had an ~83% survival rate against ZIKV
R103451 challenge, all pups born to the E298-409- and
E296-406-immunized mice survived the R103451 chal-
lenge (Fig. 3a), and all pups born to the E298-409-, E296-
406-, and E301-404-immunized mice survived the FLR
challenge (Fig. 3b). All pups born to the above three EDIII
fragment-immunized mice had increased weights during
the detection period (14 days) after challenge with both
R103451 (Fig. 3c) and FLR (Fig. 3d) strains. The evalua-
tion of the neutralizing antibodies revealed that, similar to
the immunized mothers, pups from E298-409-immunized
mice had the highest neutralizing antibody titers among
the three treatments against R103451 (Fig. 3e) and FLR
(Fig. 3f) strains. In contrast to the above results, pups born
to the mice injected with PBS did not survive challenge
with the R103451 (Fig. 3a) and FLR (Fig. 3b) strains, and
all of them died at 10 and 11 days p.i., respectively, with
decreased weights 4 and 6 days post-challenge with
R103451 (Fig. 3c) or FLR (Fig. 3d). This result is mainly
because no neutralizing antibodies were detected in the
mothers injected with PBS (Fig. 3e, f). The above results
demonstrated that pups born to mice immunized with
ZIKV EDIII fragments, particularly E298-409, were pro-
tected against infection with divergent ZIKV strains,
possibly because maternal neutralizing antibodies had
been transferred via placenta from mothers to fetuses
during pregnancy.
Fig. 1 ZIKV EDIII fragments induced neutralizing antibodies against divergent human, mosquito, and rhesus strains of ZIKV. Mouse sera
from 2 months post immunization with ZIKV EDIII fragments or PBS control were tested by PRNT assay against infection with ZIKV strains isolated
from human, including FLR (a), R103451 (b), PAN2015 (c), PAN2016 (d), PRVABC59 (e), PLCal_ZV (f), and IbH 30656 (g), as well as from mosquito, MEX
2-81 (h), and rhesus, MR 766 (i). Neutralizing activity is expressed as 50% neutralizing antibody titer (PRNT50), and the data are presented as the
means ± SE of the mice in each group (n = 5). Signiﬁcant differences were noted between E208-409 and the other two EDIII fragments against FLR
(**P < 0.01), R103451 (*P < 0.05), PLCal_ZV (*P < 0.05), and IbH 30656 (**P < 0.01), respectively. The experiments were repeated twice, and similar
results were obtained
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Fig. 2 ZIKV EDIII fragments induced long-term antibody responses and neutralizing antibodies against infection with two epidemic
human ZIKV strains. (A) Mouse sera collected before immunization and 2, 7, and 10 months post immunization with ZIKV EDIII fragments or PBS
control were tested by ELISA for ZIKV EDIII (a) and/or E (b)-speciﬁc IgG, IgG1 (c), and IgG2a (d) antibodies. The antibody titers were expressed as the
endpoint dilutions that remained positively detectable and are presented as the means ± SE of the mice in each group (n = 5). For EDIII-speciﬁc IgG
(a), signiﬁcant differences were observed between E298-409 and E296-406 at 2, 7, and 10 months (*P < 0.05), and between E296-406 and E301-404 at
10 months (*P < 0.05) post immunization. For E-speciﬁc IgG (b), signiﬁcant differences were found between E298-409 and E296-406 at 2, 7 (*P < 0.05),
and 10 months (**P < 0.01), and between E296-406 and E301-404 at 7 (*P < 0.05) and 10 months (**P < 0.01) post immunization. For IgG1, signiﬁcant
differences were noted between E298-409 and E296-406 (**P < 0.01), and between E298-409 and E301-404 (*P < 0.05) at 7 months post
immunization. For IgG2a, signiﬁcant differences occurred between E298-408 and E296-406 at 2 months (**P < 0.01), and between E298-409 or E301-
404 and E296-406 (*P < 0.05) at 7 months post immunization. (B) The aforementioned sera were tested by PRNT assay against infection with ZIKV
R103451 (a) or FLR (b) strain. The neutralizing antibody titers were expressed as PRNT50 and are presented as the means ± SE of the mice in each
group (n = 5). Signiﬁcant differences occurred between E298-409 and the other two EDIII fragments against R103451 (*P < 0.05) and FLR (**P < 0.01),
respectively, at the indicated months post immunization. The experiments were repeated twice, and similar results were obtained
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Adoptive transfer of ZIKV E298-409-immunized mouse
sera completely protected naive pups against challenge
with divergent epidemic human ZIKV strains
To elucidate the mechanism of ZIKV EDIII fragments in
protecting against ZIKV infection and understand the
correlation between neutralizing antibodies and protection,
7-day-old pups born to naive BALB/c mice were passively
transferred with sera (equal to 104 ZIKV EDIII-speciﬁc IgG
titer) from mice immunized with ZIKV EDIII fragments. 6
h later, these pups were challenged with 5× 104 PFU of
ZIKV R103451 or FLR, and then observed for survival and
weight change. Pups transferred with anti-E298-409 sera,
which had a higher neutralizing antibody titer than either
the anti-E296-406 or anti-E301-404 sera against ZIKV
R103451 (Fig. 4a) and FLR (Fig. 4b), exhibited the highest
survival rates among the three groups after challenge with
Fig. 3 ZIKV EDIII fragments protected pups born to immunized BALB/c mice against challenge with two epidemic human ZIKV strains.
Groups of 7-day-old pups (n = 6) born to female BALB/c mice immunized with ZIKV EDIII fragments or PBS control were challenged with ZIKV (5 × 104
PFU), and percentages of survival in the ZIKV R103451 (a) or FLR (b) strain treatments, as well as percentages of weight in the ZIKV R103451 (c) or FLR
(d) treatments, were recorded for 14 days p.i. The data in c and d are presented as the means ± SE of surviving pups in each group. Neutralizing
antibody titers of sera of mothers at the time of pregnancy and surviving pups at 14 days p.i. in the ZIKV R103451 (e) or FLR (f) strain treatments are
expressed as PRNT50. The data are presented as the means ± SE of sera of pregnant mothers (n = 5) or surviving pups in each group, and the
experiments were repeated twice with similar results. Signiﬁcant differences (*P < 0.05) between E298-409 and E296-406 or E301-404 are shown
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both ZIKV strains (Fig. 4c, d). As expected, pups receiving
anti-E301-404 sera, which had the lowest neutralizing
antibody titer against both R103451 and FLR (Fig. 4a, b),
had the lowest survival rates among the three groups after
challenge with R103451 and FLR (Fig. 4c, d). Clearly, pups
receiving sera of mice immunized with all three EDIII
fragments were able to maintain their body weight after
challenge with both ZIKV strains (Fig. 4e, f). In contrast,
pups in the sham controls did not survive ZIKV challenge,
and all pups died at 12 and 11 days p.i., respectively, of
R103451 and FLR strains (Fig. 4c, d), with continually
decreasing weights after 6 days post-challenge with both
ZIKV strains (Fig. 4e, f).
As one dose of anti-E298-409 sera could not fully pro-
tect the pups against ZIKV infection, pups were given an
additional dose of these sera 12 h post-challenge with
Fig. 4 Adoptive transfer of ZIKV EDIII-immunized mouse sera protected pups born to naïve BALB/c mice against challenge with two
epidemic human ZIKV strains. Groups of 7-day-old pups (n = 6) born to naive BALB/c mice were adoptively transferred with sera of mice
immunized with EDIII fragments and challenged with ZIKV (5 × 104 PFU) 6 h later. The neutralizing antibody titers (PRNT50) from adoptively
transferred sera in the ZIKV R103451 (a) or FLR (b) strain treatments are shown. All sera were adjusted to an equal titer (104) of IgG antibody speciﬁc to
ZIKV EDIII. Percentages of survival of pups challenged with ZIKV R103451 (c) or FLR (d), as well as percentages of weight of pups challenged with ZIKV
R103451 (e) or FLR (f), were recorded for 14 days p.i. The data in e and f are presented as the means ± SE of surviving pups in each group. Pups
infected with ZIKV only were included as sham controls. “Two doses” (in c–f) indicates that pups were adoptively transferred with two doses of the
above sera 6 h before and 12 h after ZIKV infection
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ZIKV. Interestingly, these pups were completely protected
from R103451 and FLR challenge (Fig. 4c, d), and their
weights steadily increased during the observation period
(Fig. 4e, f). These data conﬁrmed that the protection level
in pups against ZIKV infection is associated with the
amount of the neutralizing antibodies induced by the
ZIKV EDIII fragments.
Protective efﬁcacy of E298-409 of ZIKV EDIII against
divergent epidemic human ZIKV strains in ZIKV-
susceptible A129 mice
Given that the pups born to the mother mice immu-
nized with E298-409 and the pups receiving anti-E298-
409 sera were fully protected from ZIKV infection, we
then tested whether anti-E298-409 sera could also protect
Fig. 5 Adoptive transfer of sera of mice immunized with E298-409 of ZIKV EDIII protected lethal A129 mice against challenge with two
epidemic human ZIKV strains. The following three experiments were carried out in 5-week-old A129 mice (n = 6). Mice infected with ZIKV only
were included as sham controls. (1) Mice were passively transferred with anti-E298-409 sera (e.g., 105 ZIKV EDIII-speciﬁc IgG antibody titer), then
challenged with ZIKV R103451 (102 PFU) 6 h later, and percentages of survival (a) and weight (b) were calculated for 14 days p.i. (2) Mice were
passively transferred with the above sera 6 h before and 12 h after infection with the ZIKV FLR (c, d) or R103451 (e, f) (103 PFU) strains, and
percentages of survival were recorded for FLR (c) and R103451 (e), as well as weights from FLR (d) and R103451 (f), for 14 days p.i. (3) Mice were
passively transferred with the above sera 6 h before and 12, 24, and 48 h post-challenge with ZIKV R103451 (103 PFU), and percentages of survival (g)
and weight (h) were recorded for 14 days p.i. The data in b, d, f, and g are presented as the means + SE of surviving mice in each group
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type I interferon receptor-deﬁcient adult A129 mice,
which are highly susceptible to ZIKV infection, against
lethal ZIKV challenge. Anti-E298-409 sera equal to 105
ZIKV EDIII-speciﬁc IgG titer and neutralizing antibody
titers of 3.6× 102 and 1.3× 102, respectively, against
R103451 and FLR infection, were adoptively transferred
into adult A129 mice, and survival and weight change
were recorded in the challenged mice. Three different
challenge experiments were performed in A129 mice.
First, mice received sera 6 h before infection with 102 PFU
of ZIKV R103451 (Fig. 5a, b). Second, mice received sera
6 h before and 12 h after infection with a higher titer (103
PFU) of ZIKV FLR (Fig. 5c, d) or R103451 (Fig. 5e, f).
Third, mice received sera 6 h before and 12, 24, and 48 h
after infection with 103 PFU of ZIKV R103451 (Fig. 5g, h).
The results of the ﬁrst experiment demonstrated
that, while the sham control mice did not survive from
ZIKV challenge (102 PFU) and showed increased
weight loss, A129 mice receiving anti-E298-409 neu-
tralizing sera had 100% survival after ZIKV R103451
infection (Fig. 5a) with increased weight after challenge
(Fig. 5b). This result suggests that anti-E298-409 anti-
bodies can also protect immunocompromised adult mice
from ZIKV infection. The data from the second experi-
ment revealed that A129 mice passively transferred with
anti-E298-409 sera were protected against challenge with
a higher titer (103 PFU) of ZIKV FLR (Fig. 5c, d) or
R103451 (Fig. 5e, f) strains. The results of the third
experiment indicated that increased doses of passively
transferred anti-E298-409 sera with neutralizing activity
enhanced A129 mouse survival (Fig. 5g) and slightly
increased weight (Fig. 5h) after R103451 challenge. In
both the second and third experiments, all control A129
mice receiving 103 PFU of ZIKV R103451 or FLR died at
8 days p.i. (Fig. 5c, e, and g) with decreased weights
(Fig. 5d, f, and h).
The ability of anti-E298-409 sera to inhibit ZIKV
replication was evaluated in A129 mice by qRT-PCR at
3 days p.i. to detect viral titers in tissues and sera and by
H&E staining at 5 days p.i. to evaluate pathological
changes in tissues. The qRT-PCR results demonstrated
that mice receiving anti-E298-409 sera had signiﬁcantly
reduced viral titers in tissues, including brain, lung, liver,
spleen, and kidney, and sera after challenge with ZIKV
R103451 or FLR strain, compared with the sham control
mice that did not receive sera (Fig. 6A). Analysis of
pathological changes revealed that control A129 mice had
severe brain damage with enhanced neuronal eosinophi-
lia, neuronal necrosis, T-cell proliferation, and focal
bleeding in the brain tissues (Fig. 6Bb), as well as serious
interstitial inﬂammation, focal bleeding, epithelial cell
degeneration, and inﬂammatory cell inﬁltration in the
lung tissues (Fig. 6Bd). In contrast, the anti-E298-409
sera-treated A129 mice demonstrated considerable
alleviation of tissue damage, along with signiﬁcantly
decreased neuronal eosinophilia and T-cell proliferation
in the brain tissues (Fig. 6Ba) and slight interstitial
inﬂammation, epithelial cell degeneration, and inﬂam-
matory cell inﬁltration in the lung tissues (Fig. 6Bc).
This line of evidence conﬁrmed that the protection of
A129 mice against ZIKV challenge was positively corre-
lated with the amount of neutralizing antibodies, sug-
gesting that the protection is mediated by the EDIII-
speciﬁc neutralizing antibodies. These results further
demonstrated the protective efﬁcacy of the identiﬁed
EDIII fragment against divergent human epidemic ZIKV
strains.
Discussion
In this study, we explored the potential for developing
effective and safe ZIKV EDIII-based vaccines with potent
neutralizing activity and protective efﬁcacy against ZIKV
infection. By comparing the cross-neutralization and
protection of three recombinant vaccines encoding ZIKV
EDIII fragments of different lengths, we identiﬁed a cri-
tical neutralizing fragment containing residues 298–409 of
EDIII (e.g., E298-409) that induced the highest titers of
cross-neutralizing antibodies against infection with nine
ZIKV strains with different or the same EDIII sequences
isolated from different hosts, regions, and time periods.
The identiﬁed E298-409 fragment with the highest neu-
tralizing potential had the protective efﬁcacy to protect
newborns and lethal adult A129 mice against the two
epidemic human strains of ZIKV tested. These data sug-
gest that the N- and C-terminal residues of ZIKV EDIII
have important roles in inducing protective neutralizing
antibodies and that an appropriate extension of EDIII
residues to the N-terminal DI region and C-terminal stalk
region (Supplementary Figure S1) helps in the production
of effective neutralizing antibodies against ZIKV infection.
Previous studies have identiﬁed several ZIKV EDIII-
speciﬁc mouse neutralizing mAbs, such as ZV-5436. Here,
we found that, similar to ZV-54mAb, which maintained
the highest neutralizing capacity (the lowest ND50) in
neutralizing R103451 (Supplementary Figure S5), a recent
human ZIKV strain, anti-E298-409 pAb also had the
highest neutralizing activity against this viral strain
(Fig. 1). In addition, both EDIII-speciﬁc pAb and mAb can
effectively neutralize other epidemic human ZIKV strains
tested, including FLR, PAN2015, PAN2016, and
PRVABC59 (Fig. 1; Supplementary Figure S5), suggesting
a broad neutralizing capacity of ZIKV EDIII-speciﬁc
antibodies against infection with ZIKV, particularly the
pandemic human strains. As a number of variations have
been demonstrated in the different strains of ZIKV tested,
including viral E proteins (Supplementary Figure S4), the
ability of the identiﬁed critical neutralizing domain of
EDIII (e.g., E298-409) to induce cross-neutralization and
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protective efﬁcacy will be beneﬁcial and provide useful
guidance for the development of effective vaccines to
protect against current and future epidemic ZIKV strains.
ZIKV infection remains a serious health threat to
pregnant women due to the ability of ZIKV to cross the
placenta and infect fetuses, leading to severe birth
defects3–5,39. Therefore, it is critically important to
develop vaccines with potent efﬁcacy to protect pregnant
women, as well as their fetuses and newborns, against
ZIKV infection, reducing the occurrence of CZS, parti-
cularly microcephaly. In this study, we evaluated the
ability of ZIKV EDIII fragments to protect against ZIKV
infection in pups born to immunized female mice. We
conﬁrmed that the pups born to E298-409-immunized
mice had highly potent neutralizing antibody responses
and were fully protected against lethal ZIKV challenge.
Fig. 6 Adoptive transfer of sera of mice immunized with E298-409 of ZIKV EDIII signiﬁcantly alleviated viral replication and pathological
effects in ZIKV-infected A129 mice. (A) Five-week-old A129 mice (n = 6) were passively transferred with anti-E298-409 sera (e.g., 105 ZIKV EDIII-
speciﬁc IgG antibody titer), challenged with ZIKV R103451 or FLR (103 PFU) strains 6 h before and 12 h after infection, and detected for ZIKV RNA by
qRT-PCR in tissues (brain, lung, kidney, liver, and spleen) and sera at 3 days p.i. The data are presented as the means ± SE of six mice in each group.
The experiments were repeated twice and similar results were obtained. Signiﬁcant differences (*P < 0.05; **P < 0.01; ***P < 0.001) were seen between
E298-409 and sham control groups in the test tissues and sera. (B) Five-week-old A129 mice were passively transferred with anti-E298-409 sera (a, c),
infected with ZIKV R103451 as above, and detected for pathological changes at 5 days p.i. Representative images from mouse brain (a, b) and lung (c,
d) tissues are shown. The H&E-stained tissue sections were observed under light microscopy (×10 magniﬁcation). Sham control, A129 mice infected
with ZIKV R103451
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These results suggest that the neutralizing antibodies in
fetuses transferred via placenta from immunized pregnant
mothers are effective in protecting the newborns from
ZIKV infection, thus providing evidence to show the
effectiveness of immunizing pregnant women with an
EDIII-based vaccine for the protection of fetuses or
newborns against ZIKV infection.
Protective efﬁcacy against ZIKV is mainly associated
with neutralizing antibodies targeting the viral E pro-
tein23,36,40,41. Indeed, the present study has demonstrated
that passive transfer of ZIKV EDIII-speciﬁc neutralizing
antibodies could protect naive newborns against ZIKV
infection. Particularly, adoptively transferred neutralizing
mouse sera speciﬁc to the identiﬁed E298-409 fragment
conferred to newborns complete protection against lethal
challenge with two epidemic human ZIKV strains. Such
sera with neutralizing activity were also protective against
infection with the above two ZIKV strains in type I
interferon receptor-deﬁcient adult A129 mice, signiﬁcantly
preventing viral replication and increasing mouse survival.
These results suggest that E298-409-speciﬁc neutralizing
antibodies can effectively protect normal newborn babies
and immunocompromised adults from ZIKV infection and
that protection against ZIKV infection is positively asso-
ciated with the amount of these neutralizing antibodies.
Overall, this study has identiﬁed a critical fragment
overlapping ZIKV EDIII, E298-409, for developing effec-
tive and safe ZIKV vaccines. The expressed protein con-
taining E298-409 shows promise for further development
as an efﬁcacious and safe vaccine for prevention of ZIKV
infection in high-risk populations, particularly pregnant
women and their fetuses. E298-409-speciﬁc neutralizing
antibodies may also be used for pre-exposure prophylaxis
of ZIKV infection in newborn babies and immunocom-
promised adults.
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